Precision Biosciences (DTIL) Amortizatization of Intangibles (2020 - 2026)
Precision Biosciences (DTIL) posted quarterly Amortizatization of Intangibles of $117000.0 for Q1 2026, down 11.36% year-over-year from $132000.0 in Q1 2025, and up 431.82% quarter-over-quarter from $22000.0 in Q4 2025.
Precision Biosciences (DTIL) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Amortizatization of Intangibles for 7 consecutive years, with $117000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 11.36% year-over-year to $117000.0; the TTM figure through Mar 2026 stood at $171000.0 (up 11.04% YoY), while the FY2025 annual figure was $186000.0, down 25.3% from the prior year.
- Amortizatization of Intangibles improved to $117000.0 in Q1 2026 per DTIL's latest filing, from $22000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $227000.0 in Q1 2024 and bottomed at -$27000.0 in Q3 2024.
- Historically, Amortizatization of Intangibles has averaged $71470.6 across 5 years, with a median of $52000.0 in 2023.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles soared 1152.94% — and 2024, when it sank 151.92%.
- Precision Biosciences' Amortizatization of Intangibles stood at $85000.0 in 2022, then slumped by 37.65% to $53000.0 in 2023, then tumbled by 60.38% to $21000.0 in 2024, then rose by 4.76% to $22000.0 in 2025, then soared by 431.82% to $117000.0 in 2026.
- Business Quant data shows DTIL's Amortizatization of Intangibles at $117000.0 in Q1 2026, $22000.0 in Q4 2025, and $18000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | 350,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,000.00 |
| Jun 30, 2026 | -2,000.00 |
| Mar 31, 2026 | 117,000.00 |
| Mar 31, 2026 | 117,000.00 |
| Dec 31, 2025 | 22,000.00 |
| Dec 31, 2025 | 22,000.00 |
| Sep 30, 2025 | 18,000.00 |
| Sep 30, 2025 | 18,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 132,000.00 |
| Mar 31, 2025 | 132,000.00 |
| Dec 31, 2024 | 21,000.00 |
| Dec 31, 2024 | 21,000.00 |
| Sep 30, 2024 | -27,000.00 |
| Sep 30, 2024 | -27,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Mar 31, 2024 | 227,000.00 |
| Mar 31, 2024 | 227,000.00 |